skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Datamonitor Healthcare identifies and discusses key highlights from the American Diabetes Association 74th annual Scientific Sessions (ADA 2014) that took place between 13 June and 17 June 2014 in San Francisco, California.

ADA 2014 Conference Review

Highlights in this white paper include:   


  • Results from dulaglutide’s Phase III head-to-head trials against Victoza and Lantus.
  • Phase III results for the empagliflozin and linagliptin fixed dose combination.
  • Phase III data from Intarcia Therapeutics’ once-yearly ITCA 650.
  • Early stage data from TransTech Pharma’s oral GLP-1 agonists TTP273 and TTP054.
  • Phase III trial results for Sanofi’s Lantus follow-up Toujeo, Eli Lilly’s insulin glargine biosimilar LY2963016, and MannKind’s inhaled insulin Afrezza.
ADA 2014

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: